查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947519

生物技术领域人工智慧市场：依技术（药物发现与开发、基因组学与基因编辑、精准医疗、生物加工与製造、诊断与成像）、部署类型（云端、本地部署）和应用领域划分——全球预测至2036年

AI in Biotechnology Market by Technology (Drug Discovery & Development, Genomics & Gene Editing, Precision Medicine, Bioprocessing & Manufacturing, Diagnostics & Imaging), Deployment (Cloud-based, On-premise), End-use - Global Forecast to 2036
出版日期: | 出版商: Meticulous Research | 英文 277 Pages | 商品交期: 5-7个工作天内

价格
简介目录

全球生物技术领域人工智慧（AI）市场预计将以21.8%的复合年增长率成长，从2026年的64.1亿美元成长到2036年的约461亿美元。本报告对全球五大主要地区的生物技术领域人工智慧市场进行了详细分析，重点关注当前市场趋势、市场规模、最新发展以及至2036年的预测。

基于广泛的一手和二手研究以及对市场现状的深入分析，本报告对关键行业驱动因素、限制因素、机会和挑战进行了影响分析。 推动生物技术领域人工智慧市场成长的关键因素包括计算生物学与生物科学的加速融合，以及药物发现和个人化治疗方案的突破性创新。此外，基因组资料集的快速成长、复杂疾病环境下对高通量筛选日益增长的需求，以及先进人工智慧演算法的整合，预计也将为生物技术领域人工智慧企业创造巨大的成长机会。

市场区隔

目录

第一章：引言

第二章：摘要整理

第三章：市场概览

  • 市场动态
    • 驱动因素
    • 限制因素
    • 机遇
    • 挑战
  • 生成式人工智慧及其底层模型对生物技术的影响
  • 监理环境与伦理考量
  • 波特五力分析

第四章：全球生物技术领域人工智慧市场（依技术划分）

  • 药物发现与开发
    • 标靶识别与验证
    • 先导化合物生成与最佳化
    • 临床前开发
    • 临床试验设计与最佳化
  • 基因体学与基因编辑
    • 基因体定序与分析
    • CRISPR与基因治疗设计
    • 功能基因体学
  • 精准医疗
    • 患者分层与生物标记发现
    • 治疗反应预测
    • 个人化治疗方案製定
  • 生物加工与生产
    • 製程优化
    • 品质控制与监测
    • 产量预测与提升
  • 诊断与影​​像
    • 医学影像分析
    • 数位病理学
    • 疾病检测与筛检
  • 其他（蛋白质工程、合成生物学、农业生物技术）

第五章：全球生物技术领域人工智慧市场依部署类型划分

  • 云端部署
  • 本地部署
  • 混合部署

第六章：全球生物技术领域人工智慧市场依最终用途划分

  • 製药公司
    • 大药厂
    • 中小型製药公司
  • 生技公司
  • 研究机构与学术中心
  • 医院和诊断中心
  • 合约研究组织 (CRO)

第七章：全球生物技术领域人工智慧市场依地区划分

  • 北美
    • 美国美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 瑞士
    • 义大利
    • 西班牙
    • 荷兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 新加坡
    • 韩国
    • 澳大利亚
    • 其他亚太国家
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲国家非洲

第八章 竞争格局

  • 关键成长策略
  • 竞争标竿分析
  • 竞争概览
    • 行业领导者
    • 市场差异化因素
    • 先锋企业
    • 新兴企业
  • 主要企业市场排名/定位分析（2025 年）

第9章 企业简介(产业概要，财务概要，产品系列，策略性展开，SWOT分析)

  • IBM Watson Health(IBM Corporation)
  • Google DeepMind(Alphabet Inc.)
  • Microsoft Corporation
  • NVIDIA Corporation
  • BenevolentAI
  • Exscientia plc
  • Recursion Pharmaceuticals, Inc.
  • Insilico Medicine
  • Atomwise, Inc.
  • Insitro
  • PathAI
  • Tempus AI, Inc.
  • SOPHiA GENETICS
  • Freenome Holdings, Inc.
  • Aidoc Medical Ltd.

第10章 附录

简介目录
Product Code: MRHC - 1041787

AI in Biotechnology Market by Technology (Drug Discovery & Development, Genomics & Gene Editing, Precision Medicine, Bioprocessing & Manufacturing, Diagnostics & Imaging), Deployment (Cloud-Based, On-Premise), End-Use, and Geography - Global Forecast to 2036

According to the research report titled, 'AI in Biotechnology Market by Technology (Drug Discovery & Development, Genomics & Gene Editing, Precision Medicine, Bioprocessing & Manufacturing, Diagnostics & Imaging), Deployment (Cloud-Based, On-Premise), End-Use, and Geography - Global Forecast to 2036,' the global AI in biotechnology market is expected to reach approximately USD 46.1 billion by 2036 from USD 6.41 billion in 2026, at a CAGR of 21.8% during the forecast period (2026-2036). The report provides an in-depth analysis of the global AI in biotechnology market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036.

Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The major factors driving the growth of the AI in biotechnology market include the accelerating convergence of computational biology and biological sciences and the breakthrough innovations in drug discovery and personalized treatment protocols. Additionally, the rapid expansion of genomic datasets, increasing need for high-throughput screening in complex disease environments, and integration of advanced AI algorithms are expected to create significant growth opportunities for players operating in the AI in biotechnology market.

Market Segmentation

The AI in biotechnology market is segmented by technology (drug discovery & development, genomics & gene editing, precision medicine, bioprocessing & manufacturing, diagnostics & imaging), deployment (cloud-based, on-premise), end-use, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on Technology

By technology, the drug discovery & development segment holds the largest market share in 2026, primarily attributed to its critical role in supporting small molecule design, target identification, and accelerated clinical candidate optimization. AI-powered drug discovery platforms provide substantial competitive advantages in biological research and clinical translation. However, the genomics & gene editing segment is expected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of AI for genetic sequence analysis and CRISPR-based therapeutic development. The ability to deliver integrated solutions with proven clinical validation makes advanced genomics AI platforms highly attractive for biotechnology companies.

Based on Deployment

By deployment, the cloud-based segment holds the largest market share in 2026, owing to its scalability and ability to handle massive biological datasets with collaborative research workflows. Cloud-based AI platforms provide superior accessibility for distributed research teams and institutions. The on-premise segment is expected to witness significant growth during the forecast period, driven by the need for data security compliance and the requirement for real-time processing in specialized laboratory environments. Organizations with stringent intellectual property and regulatory requirements continue to favor on-premise deployment models for sensitive research applications.

Based on End-Use

By end-use, the pharmaceutical companies segment holds the largest share of the overall market in 2026, due to their substantial investments in computational biology infrastructure and the need for accelerated drug development pipelines. Pharmaceutical organizations represent the primary adopters of AI biotechnology solutions. The biotechnology companies segment is expected to grow at a significant CAGR during the forecast period, driven by the increasing adoption of AI for research acceleration and the development of specialized AI-powered therapeutic platforms. Academic research institutions and contract research organizations represent emerging segments with growing adoption of advanced AI biotechnology tools.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global AI in biotechnology market with the largest market share, primarily attributed to substantial investments in computational biology infrastructure and the concentration of leading pharmaceutical innovators in the United States and Canada. Asia-Pacific is expected to witness the fastest growth during the forecast period, supported by expanding biotech research capabilities and government initiatives promoting AI-driven healthcare innovation in China, India, and Singapore. Europe, Latin America, and the Middle East & Africa represent emerging markets with growing biotechnology research infrastructure and increasing adoption of advanced AI technologies.

Key Players

The key players operating in the global AI in biotechnology market are IBM Corporation, Microsoft Corporation, Google LLC, NVIDIA Corporation, Schrodinger, Atomwise, Recursion Pharmaceuticals, Exscientia, DeepMind (Alphabet), and various other regional and emerging biotechnology AI solution providers, among others.

Key Questions Answered in the Report-

  • What is the current revenue generated by the AI in biotechnology market globally?
  • At what rate is the global AI in biotechnology market demand projected to grow for the next 7-10 years?
  • What are the historical market sizes and growth rates of the global AI in biotechnology market?
  • What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of technology, deployment, and end-use are expected to create major traction for the service providers in this market?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global AI in biotechnology market?
  • Who are the major players in the global AI in biotechnology market? What are their specific product offerings in this market?
  • What are the recent strategic developments in the global AI in biotechnology market? What are the impacts of these strategic developments on the market?

Scope of the Report:

AI in Biotechnology Market Assessment -- by Technology

  • Drug Discovery & Development
  • Genomics & Gene Editing
  • Precision Medicine
  • Bioprocessing & Manufacturing
  • Diagnostics & Imaging

AI in Biotechnology Market Assessment -- by Deployment

  • Cloud-Based
  • On-Premise

AI in Biotechnology Market Assessment -- by End-Use

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic Research Institutions
  • Contract Research Organizations

AI in Biotechnology Market Assessment -- by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Singapore
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Scope
  • 1.3. Research Methodology
  • 1.4. Assumptions & Limitations

2. Executive Summary

3. Market Overview

  • 3.1. Introduction
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
    • 3.2.4. Challenges
  • 3.3. Impact of Generative AI and Foundation Models on Biotechnology
  • 3.4. Regulatory Landscape & Ethical Considerations
  • 3.5. Porter's Five Forces Analysis

4. Global AI in Biotechnology Market, by Technology

  • 4.1. Introduction
  • 4.2. Drug Discovery & Development
    • 4.2.1. Target Identification & Validation
    • 4.2.2. Lead Generation & Optimization
    • 4.2.3. Preclinical Development
    • 4.2.4. Clinical Trial Design & Optimization
  • 4.3. Genomics & Gene Editing
    • 4.3.1. Genome Sequencing & Analysis
    • 4.3.2. CRISPR & Gene Therapy Design
    • 4.3.3. Functional Genomics
  • 4.4. Precision Medicine
    • 4.4.1. Patient Stratification & Biomarker Discovery
    • 4.4.2. Treatment Response Prediction
    • 4.4.3. Personalized Treatment Planning
  • 4.5. Bioprocessing & Manufacturing
    • 4.5.1. Process Optimization
    • 4.5.2. Quality Control & Monitoring
    • 4.5.3. Yield Prediction & Enhancement
  • 4.6. Diagnostics & Imaging
    • 4.6.1. Medical Imaging Analysis
    • 4.6.2. Digital Pathology
    • 4.6.3. Disease Detection & Screening
  • 4.7. Others (Protein Engineering, Synthetic Biology, Agricultural Biotechnology)

5. Global AI in Biotechnology Market, by Deployment

  • 5.1. Introduction
  • 5.2. Cloud-based
  • 5.3. On-premise
  • 5.4. Hybrid

6. Global AI in Biotechnology Market, by End-use

  • 6.1. Introduction
  • 6.2. Pharmaceutical Companies
    • 6.2.1. Large Pharmaceutical Companies
    • 6.2.2. Small & Medium Pharmaceutical Companies
  • 6.3. Biotechnology Companies
  • 6.4. Research Institutes & Academic Centers
  • 6.5. Hospitals & Diagnostic Centers
  • 6.6. Contract Research Organizations (CROs)

7. Global AI in Biotechnology Market, by Region

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Europe
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Switzerland
    • 7.3.5. Italy
    • 7.3.6. Spain
    • 7.3.7. Netherlands
    • 7.3.8. Rest of Europe
  • 7.4. Asia-Pacific
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. India
    • 7.4.4. Singapore
    • 7.4.5. South Korea
    • 7.4.6. Australia
    • 7.4.7. Rest of Asia-Pacific
  • 7.5. Latin America
    • 7.5.1. Brazil
    • 7.5.2. Mexico
    • 7.5.3. Argentina
    • 7.5.4. Rest of Latin America
  • 7.6. Middle East & Africa
    • 7.6.1. Saudi Arabia
    • 7.6.2. UAE
    • 7.6.3. Israel
    • 7.6.4. South Africa
    • 7.6.5. Rest of Middle East & Africa

8. Competitive Landscape

  • 8.1. Overview
  • 8.2. Key Growth Strategies
  • 8.3. Competitive Benchmarking
  • 8.4. Competitive Dashboard
    • 8.4.1. Industry Leaders
    • 8.4.2. Market Differentiators
    • 8.4.3. Vanguards
    • 8.4.4. Emerging Companies
  • 8.5. Market Ranking / Positioning Analysis of Key Players, 2025

9. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis)

  • 9.1. IBM Watson Health (IBM Corporation)
  • 9.2. Google DeepMind (Alphabet Inc.)
  • 9.3. Microsoft Corporation
  • 9.4. NVIDIA Corporation
  • 9.5. BenevolentAI
  • 9.6. Exscientia plc
  • 9.7. Recursion Pharmaceuticals, Inc.
  • 9.8. Insilico Medicine
  • 9.9. Atomwise, Inc.
  • 9.10. Insitro
  • 9.11. PathAI
  • 9.12. Tempus AI, Inc.
  • 9.13. SOPHiA GENETICS
  • 9.14. Freenome Holdings, Inc.
  • 9.15. Aidoc Medical Ltd.

10. Appendix

  • 10.1. Questionnaire
  • 10.2. Related Reports